<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00170326</url>
  </required_header>
  <id_info>
    <org_study_id>PreVent-HF</org_study_id>
    <nct_id>NCT00170326</nct_id>
  </id_info>
  <brief_title>Progressive Ventricular Dysfunction Prevention in Pacemaker Patients</brief_title>
  <acronym>Prevent-HF</acronym>
  <official_title>Progressive Ventricular Dysfunction Prevention in Pacemaker Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to evaluate the progression of ventricular dysfunction in
      patients with ventricular dysfunction within the permanent pacing population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The interventricular synchrony is one of the components of a proper cardiac function. When
      there is no synchrony -as in left bundle block (LBBB)- the clinic consequences should have
      little importance in patients with a healthy heart or a great importance in patients
      suffering heart failure (HF), specially in those with severe grade of HF, the benefit of
      cardiac resynchronization by pacing both ventricles or left ventricle (LV)should means
      healthy improvement in patients. All previous studies done in HF, are in patients with
      symptomatic HF. The importance of stop progression of latent HF in patients with asymptomatic
      ventricular dysfunction (VD)in permanent pacing indication patients. Pacing may accelerate HF
      progression by dissincronyzing ventricles. ACE inhibitors studies in asymptomatic VD gave
      positive results.

      The PreVent-HF is an international, multicenter, prospective, randomized, single-blinded
      pilot trial specifically designed to evaluate as main objective the progression of VD in
      permanent pacing population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Video tapes are provided by the central study organization and are labelled by numbers. The tapes are sent to the echocardiography core laboratory (Malaga, Spain) and are read by the Director of the Echo Core Lab (J.J. Gomez-Doblas). The echo examiner is blinded as to the point of time of the recording and assignment of treatment, although the presence of a LV lead may be adumbrated by visible artefacts.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of the ejection fraction (EF) of the left ventricle (LV) and the ventricular volumes.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined endpoint of cardiac mortality, appearance of HF and hospitalization due to cardiovascular problems. Morbidity.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Cardiac Pacing Indication classI/IIa According AHA/ACC</condition>
  <arm_group>
    <arm_group_label>Dual Chamber pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional dual-chamber pacemaker/ICD implantation with the ventricular lead in the right ventricular apex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biventricular pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biventricular pacing: dual-chamber biventricular pacemaker/ICD implantation with leads at the right ventricular apex and the left ventricle</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dual-chamber pacemaker implantation</intervention_name>
    <description>Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.</description>
    <arm_group_label>Dual Chamber pacing</arm_group_label>
    <other_name>DDD pacing, RV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biventricular dual-chamber pacemaker implant</intervention_name>
    <description>Biventricular pacemaker system or in case in ICD indication a BIV ICD</description>
    <arm_group_label>Biventricular pacing</arm_group_label>
    <other_name>InSync 8040, InSync III 8042</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet Class I and/or Class IIa implantation criteria for permanent cardiac pacing
             according to the guidelines given by the American College of Cardiology (ACC)/American
             Heart Association(AHA).

        Exclusion Criteria:

          -  Expected ventricle stimulation &lt;80% of the time

          -  Impossibility of dual chamber stimulation in the absence of AF

          -  Severe heart failure (NYHA Functional class III-IV) previous to indication for pacing
             device implant

          -  Patient needs revascularization within 3 months

          -  Myocardial infarction in the last 3 months

          -  Cardiac surgery performed in the last 3 months

          -  Hypertrophic cardiomyopathy

          -  Constrictive pericarditis

          -  Bad echo window

          -  Previous system implanted (ICD or pacemaker)

          -  Aortic stenosis

          -  Patient has a mechanical right heart valve

          -  Patient &lt;18 years

          -  Pregnancy

          -  Patient has medical conditions that would preclude the testing required by the
             protocol, or limit study participation

          -  Life expectancy &lt;1year

          -  Patient is unwilling or unable to cooperate or give written informed consent.

          -  Patient is or will be inaccessible for follow-up at the study center.

          -  Patients who are participating or planning to participate in other clinical trials
             during the clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo De Teresa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Alzueta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico Universitario Virgen de la Victoria, Málaga, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ignacio Fernández Lozano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta de Hierro, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan José Gómez Doblas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Navarro López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i Provincial, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Curnis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Civile Brescia, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Navarro Michel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medtronic Ibérica, S.A., Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Stockburger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite, Campus Virchow-Klinikum, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gervasio Lamas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Clinical Center, Miami, FL, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clínic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. C. U. Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>de Teresa E, Gómez-Doblas JJ, Lamas G, Alzueta J, Fernández-Lozano I, Cobo E, Navarro X, Navarro-López F, Stockburger M. Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: rationale and design of the PREVENT-HF study. Europace. 2007 Jun;9(6):442-6. Epub 2007 Apr 25.</citation>
    <PMID>17460018</PMID>
  </reference>
  <results_reference>
    <citation>Stockburger M, Gómez-Doblas JJ, Lamas G, Alzueta J, Fernández-Lozano I, Cobo E, Wiegand U, Concha JF, Navarro X, Navarro-López F, de Teresa E. Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF). Eur J Heart Fail. 2011 Jun;13(6):633-41. doi: 10.1093/eurjhf/hfr041.</citation>
    <PMID>21613427</PMID>
  </results_reference>
  <results_reference>
    <citation>Stockburger M, de Teresa E, Lamas G, Desaga M, Koenig C, Habedank D, Cobo E, Navarro X, Wiegand U. Exercise capacity and N-terminal pro-brain natriuretic peptide levels with biventricular vs. right ventricular pacing for atrioventricular block: results from the PREVENT-HF German Substudy. Europace. 2014 Jan;16(1):63-70. doi: 10.1093/europace/eut217. Epub 2013 Jul 16.</citation>
    <PMID>23861381</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Permanent Pacing artificial internal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

